How 20,000 ALS Patients’ Multiomics Data Could Transform ALS Research and Treatment

A 20,000 patient ALS multiomics dataset could transform how we understand and treat ALS, also known as MND, ALS disease, Amyotrophic lateral sclerosis, Motor Neuron disease, and Lou Gehrig’s disease. If you’ve ever searched “what is ALS?” or wondered why treatments are so limited, the answer often comes down to data — not enough of it, and not deep enough. Multiomics means studying many biological layers at once: DNA (genomics), RNA (transcriptomics), proteins (proteomics), and metabolites (metabolomics). In ALS, this could help explain why ALS symptoms and ALS stages vary so much from person to person. Why does one person progress slowly while another declines quickly? Why do some develop Bulbar ALS while others start with limb weakness? With 20,000 patients, researchers could better answer questions like: Is ALS genetic in more cases than we realize? How long do you live with ALS based on molecular subtype? Can we predict ALS prognosis earlier? Large-scale multiomics data could identify new biomarkers for earlier ALS diagnosis, track disease progression more accurately, and guide more personalized ALS treatment strategies. It could also help match patients to ALS clinical trials based on molecular subtype rather than symptoms alone. This video is for people newly diagnosed, patients living with ALS, care partners, medical professionals, and the broader ALS community who want to understand how data could drive faster breakthroughs. While there is still no ALS cure, deeper data may shorten the path to one. By combining advanced science and artificial intelligence, a 20K ALS dataset could move research from guesswork to precision.